PharmaCyte Biotech Inc (PMCB)

[Triple9]

You are being very dishonest in NOT including the word sublicensing. You are talking about SALES and we are a long way from sales. What KW did is stop the milestone payments that were happening NOW. KW stopped more capital from heading out the door in exchange for an increase in sales down the road. Seems smart to me.

People should read pages 6-7 for themselves.

http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=12268239

Right of first refusal for five years is huge and should be taken as a major indication of what the term sheet change does. It means that PMCB can confidently move to develop CiaB for pancreatic cancer without worrying Austrianova will sell CiaB in the meantime. It's a five year period, which is more than enough time for the biologic to be proven in the upcoming phase 2b trial. In five years they come back to the negotiating table and craft a new term sheet.

The fact that the term sheet was changed at all tells me more is happening behind the scenes that we don't know about.